A detailed history of Perceptive Advisors LLC transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Perceptive Advisors LLC holds 1,374,563 shares of PTGX stock, worth $57.3 Million. This represents 1.61% of its overall portfolio holdings.

Number of Shares
1,374,563
Previous 1,268,735 8.34%
Holding current value
$57.3 Million
Previous $44 Million 40.52%
% of portfolio
1.61%
Previous 1.27%

Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$33.72 - $47.33 $3.57 Million - $5.01 Million
105,828 Added 8.34%
1,374,563 $61.8 Million
Q2 2024

Aug 14, 2024

BUY
$24.66 - $34.8 $6.77 Million - $9.55 Million
274,412 Added 27.6%
1,268,735 $44 Million
Q1 2024

May 15, 2024

BUY
$21.79 - $32.15 $13.3 Million - $19.6 Million
611,063 Added 159.44%
994,323 $28.8 Million
Q4 2023

Feb 14, 2024

SELL
$14.05 - $23.44 $9.43 Million - $15.7 Million
-671,013 Reduced 63.65%
383,260 $8.79 Million
Q3 2023

Nov 14, 2023

SELL
$16.68 - $23.66 $6.93 Million - $9.83 Million
-415,488 Reduced 28.27%
1,054,273 $17.6 Million
Q2 2023

Aug 14, 2023

BUY
$18.02 - $29.36 $9.09 Million - $14.8 Million
504,609 Added 52.28%
1,469,761 $40.6 Million
Q1 2023

May 15, 2023

BUY
$10.78 - $25.38 $10.4 Million - $24.5 Million
965,152 New
965,152 $22.2 Million
Q1 2021

May 17, 2021

SELL
$19.02 - $31.15 $3.87 Million - $6.34 Million
-203,591 Closed
0 $0
Q4 2020

Feb 16, 2021

BUY
$18.49 - $25.13 $3.76 Million - $5.12 Million
203,591 New
203,591 $4.1 Million

Others Institutions Holding PTGX

About Protagonist Therapeutics, Inc


  • Ticker PTGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,084,100
  • Market Cap $2.04B
  • Description
  • Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...
More about PTGX
Track This Portfolio

Track Perceptive Advisors LLC Portfolio

Follow Perceptive Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Perceptive Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Perceptive Advisors LLC with notifications on news.